Ambalal Sarabhai

Why is Ambalal Sarabhai Enterprises Ltd falling/rising?

As of 06-Aug, Ambalal Sarabhai Enterprises Ltd's stock price has risen to Rs 43.93, reflecting a 1.93% increase. This growth is driven by strong historical performance, positive momentum, and increased investor interest, with the stock outperforming the Sensex significantly over various time frames.

As of 06-Aug, Ambalal Sarabhai Enterprises Ltd is experiencing a rise in its stock price, currently at Rs 43.93, reflecting an increase of Rs 0.83 or 1.93%. This upward movement can be attributed to several factors. Over the past week, the stock has surged by 29.24%, significantly outperforming the Sensex, which only increased by 1.32%. In the last month, the stock has risen by 36.13%, again surpassing the Sensex's 0.86% gain.<BR><BR>Year-to-date, Ambalal Sarabhai has shown a remarkable performance with a 53.71% increase, contrasting sharply with the Sensex's decline of 7.35%. The stock has also performed well over the past year, with a 37.71% rise compared to the Sensex's slight drop of 1.97%. Additionally, the stock has gained 46.68% over the last three years, while the Sensex has only increased by 20.14%, and over five years, it has risen by 38.58% compared to the Sensex's 45.46%.<BR><BR>Today's performance indicates that the stock is close to its 52-week high, being just 4.6% away from Rs 45.5. It has outperformed its sector by 0.93% today and has been on a consecutive gain streak for the last six days, accumulating a total return of 40.82% during this period. Furthermore, the stock is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating strong momentum.<BR><BR>Investor participation has also increased, with a delivery volume of 5.79 lacs on August 5, which is 45.22% higher than the 5-day average delivery volume. This suggests a growing interest in the stock, contributing to its rising price. Overall, the combination of strong historical performance, positive momentum, and increased investor activity are key factors driving the rise in Ambalal Sarabhai Enterprises Ltd's stock price.

Which are the latest news on Ambalal Sarabhai?

Should I buy, sell or hold Ambalal Sarabhai Enterprises Ltd?

What does Ambalal Sarabhai do?

Ambalal Sarabhai Enterprises Ltd is a micro-cap Indian company in the Pharmaceuticals & Biotechnology sector, focusing on manufacturing and marketing pharmaceutical and diagnostic products. As of March 2026, it reported net sales of ₹65 Cr and a net profit of ₹6 Cr, with a market cap of ₹259 Cr.

Overview: <BR>Ambalal Sarabhai Enterprises Ltd is a micro-cap company in the Pharmaceuticals & Biotechnology industry, engaged in manufacturing and marketing pharmaceutical, molecular diagnostics, and electronics products.<BR><BR>History: <BR>Incorporated on June 5, 1978, Ambalal Sarabhai Enterprises Ltd is one of the oldest pharmaceutical healthcare companies in India. The latest quarterly results reported net sales and profit for the period ending March 2026.<BR><BR>Financial Snapshot: <BR>Net Sales: 65 Cr (Quarterly Results - Mar 2026) <BR>Net Profit: 6 Cr (Quarterly Results - Mar 2026) <BR>Market Cap: INR 259 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 14.00 <BR>Industry P/E: 34 <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.23 <BR>Return on Equity: 11.67% <BR>Price to Book: 1.66 <BR><BR>Contact Details: <BR>Address: Shanti Sadan, Mirzapur Road Ahmedabad Gujarat : 380001 <BR>Tel: 91-79-25507671/25507073 <BR>Email: ketanadhvaryu@sarabhai.co.in <BR>Website: http://www.ase.life

How big is Ambalal Sarabhai?

As of 10th June, Ambalal Sarabhai Enterprises Ltd has a market capitalization of 259.00 Cr, with recent net sales of 202.28 Cr and a net profit of 17.80 Cr. The latest balance sheet shows shareholder's funds of 139.97 Cr and total assets of 268.23 Cr.

As of 10th June, Ambalal Sarabhai Enterprises Ltd has a market capitalization of 259.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Ambalal Sarabhai reported Net Sales of 202.28 Cr and a Net Profit of 17.80 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, showing Shareholder's Funds of 139.97 Cr and Total Assets of 268.23 Cr.

Who are in the management team of Ambalal Sarabhai?

The management team of Ambalal Sarabhai includes Kartikeya V Sarabhai (Chairman & Wholetime Director), Anil H Parekh (Non Executive Director), Chaula Shastri (Whole-time Director), and several independent directors, among others, who oversee the company's governance and strategic direction.

The management team of Ambalal Sarabhai includes the following key members:<BR><BR>1. **Kartikeya V Sarabhai** - Chairman & Wholetime Director<BR>2. **Anil H Parekh** - Non Executive Director<BR>3. **Ashwin P Hathi** - Independent Director<BR>4. **Chaula Shastri** - Whole-time Director<BR>5. **Chandrashekhar B. Bohra** - Independent Director<BR>6. **Damodar Sejpal** - Company Secretary & Compliance Officer<BR>7. **Mayur K Swedia** - Independent Director<BR>8. **Brijesh Khandelwal** - Director and Additional Director<BR><BR>This team plays a crucial role in the governance and strategic direction of the company.

Who are the peers of the Ambalal Sarabhai?

Ambalal Sarabhai's peers include Medico Remedies, Medicamen Biotec, Trident Lifeline, and others, with varying management risks and growth rates. Astonea Labs leads in 1-year returns at 58.56%, while Ambalal Sarabhai has a return of -13.17%.

Peers: The peers of Ambalal Sarabhai are Medico Remedies, Medicamen Biotec, Trident Lifeline, Zenotech Lab., Lyka Labs, Astonea Labs, Everest Organics, Gennex Lab., and Infinium Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Gennex Lab. and Sat Kartar, while Average management risk is found at Medicamen Biotec, Trident Lifeline, Zenotech Lab., Lyka Labs, Astonea Labs, Everest Organics, and Infinium Pharma, and the rest. Good management risk is noted at Medico Remedies. Below Average management risk is present at Ambalal Sarabhai and Infinium Pharma. Growth is Excellent at Trident Lifeline and Astonea Labs, Good at Gennex Lab., Zenotech Lab., and Medico Remedies, Average at Ambalal Sarabhai, and Below Average at Medicamen Biotec, Lyka Labs, Everest Organics, and the rest. Capital Structure is Excellent at Medicamen Biotec and Gennex Lab., Good at Medico Remedies, Trident Lifeline, and Zenotech Lab., Average at Ambalal Sarabhai, and Below Average at Lyka Labs, Astonea Labs, Everest Organics, and the rest.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Astonea Labs at 58.56%, while the lowest is Medicamen Biotec at -46.53%. Ambalal Sarabhai's 1-year return of -13.17% is better than Medicamen Biotec's but worse than Astonea Labs'. Additionally, Everest Organics, Medicamen Biotec, and Gennex Lab. have negative six-month returns.

Are Ambalal Sarabhai Enterprises Ltd latest results good or bad?

Ambalal Sarabhai Enterprises Ltd's latest results show a recovery with a net profit of ₹6.50 crores for Q4 FY26, up from a loss last year, and a 25.94% increase in net sales. However, concerns about sustainability due to reliance on non-operating income and weak capital efficiency lead to a cautious outlook, resulting in a "SELL" rating.

Ambalal Sarabhai Enterprises Ltd's latest results present a mixed picture. On one hand, the company reported a consolidated net profit of ₹6.50 crores for Q4 FY26, a significant recovery from a net loss of ₹0.27 crores in the same quarter last year, reflecting a 78.57% increase quarter-on-quarter. Additionally, net sales grew by 25.94% compared to the previous quarter, reaching ₹65.49 crores, which is the highest quarterly revenue in seven quarters.<BR><BR>However, the improvement in profitability was largely driven by non-operating income, which accounted for a substantial 41.76% of profit before tax. This raises concerns about the sustainability and quality of the earnings. The operating margin of 8.70% is the highest in seven quarters, but the year-on-year revenue growth of just 1.05% indicates challenges in generating consistent top-line momentum.<BR><BR>Furthermore, the company faces fundamental issues, such as weak capital efficiency, as evidenced by an average return on capital employed (ROCE) of only 4.36%. The reliance on non-operating income and rising interest costs also pose risks to future profitability.<BR><BR>In summary, while the latest results show a positive turnaround in profitability, the underlying structural concerns and dependency on non-core income suggest that the overall outlook remains cautious. The company has received a "SELL" rating, reflecting these ongoing challenges.

When is the next results date for Ambalal Sarabhai Enterprises Ltd?

The next results date for Ambalal Sarabhai Enterprises Ltd is 21 May 2026.

The next results date for Ambalal Sarabhai Enterprises Ltd is scheduled for 21 May 2026.

How has been the historical performance of Ambalal Sarabhai?

Ambalal Sarabhai's historical performance shows fluctuating results, with net sales increasing from 170.28 crore in March 2023 to 196.19 crore in March 2025, but profitability declined significantly, with profit after tax falling from 12.14 crore to 4.29 crore and negative cash flow from operating activities. Total liabilities and assets both rose, indicating a stable asset base despite financial challenges.

Answer:<BR>The historical performance of Ambalal Sarabhai shows a fluctuating trend in key financial metrics over the years, with notable changes in revenue and profitability.<BR><BR>Breakdown:<BR>Ambalal Sarabhai's net sales increased from 170.28 crore in March 2023 to 196.19 crore in March 2025, reflecting a growth trend. However, the total operating income showed a decline from 196.75 crore in March 2022 to 196.19 crore in March 2025. The company's total expenditure, excluding depreciation, rose from 161.71 crore in March 2023 to 188.10 crore in March 2025, impacting operating profit, which decreased from 21.06 crore in March 2023 to 19.47 crore in March 2025. Profit before tax also declined from 15.86 crore in March 2023 to 4.19 crore in March 2025, while profit after tax fell from 12.14 crore to 4.29 crore in the same period. The consolidated net profit showed a similar downward trend, decreasing from 11.45 crore in March 2023 to 4.93 crore in March 2025. On the balance sheet, total liabilities increased from 245.74 crore in March 2023 to 268.23 crore in March 2025, while total assets rose from 245.74 crore to 268.23 crore, indicating a stable asset base despite rising liabilities. Cash flow from operating activities turned negative, dropping from 5 crore in March 2023 to -17 crore in March 2025, which reflects challenges in cash generation. Overall, while revenue showed some growth, profitability and cash flow faced significant pressures during this period.

Who are the top shareholders of the Ambalal Sarabhai?

The top shareholders of Ambalal Sarabhai are Sarabhai Holdings Private Limited with 25.76%, individual investors with 57.42%, and Haryana Containers Limited as the largest public shareholder at 1.61%. There are no pledged promoter holdings or mutual funds involved.

The top shareholders of Ambalal Sarabhai include Sarabhai Holdings Private Limited, which holds the highest stake at 25.76%. Individual investors collectively own 57.42% of the company. Additionally, Haryana Containers Limited is the highest public shareholder with a holding of 1.61%. There are also two foreign institutional investors (FIIs) with a combined holding of 0.38%. Notably, there are no pledged promoter holdings and no mutual funds currently holding shares in the company.

Is Ambalal Sarabhai overvalued or undervalued?

As of June 2, 2025, Ambalal Sarabhai is considered an attractive investment due to its undervalued status, with a PE ratio of 23.05, a PEG ratio of 0.28 indicating strong growth potential, and a competitive ROE of 8.52%, despite recent underperformance against the Sensex.

As of 2 June 2025, the valuation grade for Ambalal Sarabhai has moved from fair to attractive, indicating a positive shift in its perceived value. The company is currently assessed as undervalued, particularly given its price-to-earnings (PE) ratio of 23.05, a price-to-book value of 1.96, and an EV to EBITDA ratio of 38.95. These ratios suggest that the stock is trading at a reasonable valuation compared to its earnings and book value.<BR><BR>In comparison to its peers, Ambalal Sarabhai's PE ratio aligns closely with the industry average, while its PEG ratio of 0.28 indicates strong growth potential relative to its price. Notably, its return on equity (ROE) stands at 8.52%, which is competitive within the pharmaceuticals and biotechnology sector. Despite recent underperformance against the Sensex, particularly in the year-to-date and one-year periods, the overall valuation metrics suggest that Ambalal Sarabhai presents a compelling investment opportunity at its current price of 36.70.

What is the technical trend for Ambalal Sarabhai?

As of June 4, 2025, Ambalal Sarabhai's technical trend has shifted to bearish, driven by daily moving averages and Bollinger Bands indicating bearish conditions, despite mixed signals from the MACD and KST across different time frames.

As of 4 June 2025, the technical trend for Ambalal Sarabhai has changed from mildly bearish to bearish. The current stance is bearish with moderate strength, primarily driven by the daily moving averages indicating a bearish trend and both weekly and monthly Bollinger Bands also signaling bearish conditions. The MACD shows a mildly bullish signal on the weekly chart but is mildly bearish on the monthly, suggesting mixed signals across time frames. The KST aligns with this by being mildly bullish weekly but mildly bearish monthly. Overall, the indicators reflect a bearish sentiment, particularly in the short-term daily analysis.

Has Ambalal Sarabhai declared dividend?

No Dividend History Available